Effect on AV conduction time may be potentiated & -ve inotropic effect increased w/ class-I antiarrhythmic drugs (eg, quinidine, disopyramide; lidocaine, phenytoin; flecainide, propafenone). IV administration of verapamil in patients on β-blocker may lead to profound hypotension & AV block. May increase risk of rebound HTN in abrupt w/drawal of centrally acting BP-lowering medicines (eg, clonidine, methyldopa, moxonodine, rilmenidine) particularly if prior to β-blocker discontinuation. Increased risk of hypotension, & further deterioration of the ventricular pump function in patients w/ heart failure w/ concomitant use of Ca antagonists of the dihydropyridine type (eg, nifedipine, felodipine, amlodipine). Effect on AV conduction time may be potentiated w/ class III antiarrhythmic medicines (eg, amiodarone). Topical β-blockers (eg, eye drops for glaucoma treatment) may add to the systemic effects of Concor. Concomitant use of parasympathomimetic drugs may increase AV conduction time & the risk of bradycardia. Intensification of blood sugar lowering effect w/ insulin & oral antidiabetic drugs. Attenuation of the reflex tachycardia & increased risk of hypotension w/ anaesth agents. Reduction of heart rate, increase of AV conduction time w/ digitalis glycosides. NSAIDs may reduce the hypotensive effect of bisoprolol. May reduce the effect of both bisoprolol & β sympathomimetics (eg, isoprenaline, dobutamine). Combination w/ noradrenaline, adrenaline may unmask the α-adrenoceptor-mediated vasoconstrictor effect. Increased risk of hypotension w/ antihypertensive agents as well as other drugs w/ BP lowering potential (eg, TCAs, barbiturates, phenothiazines). Increased risk of bradycardia w/ mefloquine. Enhanced hypotensive effect of β-blockers but also risk of hypertensive crisis w/ MAOIs (except MAO-B inhibitors).